Background-Information about physicians' adherence to cholesterol management guidelines remains scant. The present survey updates our knowledge of lipid management worldwide. Methods and Results-Lipid levels were determined at enrollment in dyslipidemic adult patients on stable lipid-lowering therapy in 9 countries. The primary end point was the success rate, defined as the proportion of patients achieving appropriate low-density lipoprotein cholesterol (LDL-C) goals for their given risk. The mean age of the 9955 evaluable patients was 62Ϯ12 years; 54% were male. Coronary disease and diabetes mellitus had been diagnosed in 30% and 31%, respectively, and 14% were current smokers. Current treatment consisted of a statin in 75%. The proportion of patients achieving LDL-C goals according to relevant national guidelines ranged from 47% to 84% across countries. In low-, moderate-, and high-risk groups, mean LDL-C was 119, 109, and 91 mg/dL and mean high-density lipoprotein cholesterol was 62, 49, and 50 mg/dL, respectively. The success rate for LDL-C goal achievement was 86% in low-, 74% in moderate-, and 67% in high-risk patients (73% overall). However, among coronary heart disease patients with Ն2 risk factors, only 30% attained the optional LDL-C goal of Ͻ70 mg/dL. In the entire cohort, high-density lipoprotein cholesterol was Ͻ40 mg/dL in 19%, 40 to 60 mg/dL in 55%, and Ͼ60 mg/dL in 26% of patients. Conclusions-Although there is room for improvement, particularly in very-high-risk patients, these results indicate that lipid-lowering therapy is being applied much more successfully than it was a decade ago. (Circulation. 2009;120:28-34.)
Treatment Assessment Project (L-TAP), conducted in the United States among 4888 patients in 1996 and 1997, found that LDL-C goal attainment in a primary care setting was only 38% overall and 18% among patients with established coronary heart disease (CHD). 8 In a survey undertaken in 15 European countries between 1999 and 2000, only 42% of 5226 patients with established CHD reached a total cholesterol goal of Ͻ193 mg/dL (5.0 mmol/L). 7 More recent surveys show an improvement in attaining previous LDL-C goals but low rates of reaching the new target of Ͻ70 mg/dL (1.8 mmol/L) for high-risk CHD patients. 10, 11 L-TAP 2 is a survey performed in Ͼ10 000 patients in 9 countries (United States, Canada, Mexico, Brazil, Spain, the Group guidelines were used for each corresponding geographic area. In addition to LDL-C, high-density lipoprotein cholesterol (HDL-C) and triglyceride levels were measured in patients in the fasting state.
Methods

Patient Selection
Patients were eligible if they were Ն20 years of age and if they had been treated with the same lipid-lowering therapy for at least 3 months. Diet and exercise were counted as permissible lipidlowering therapies. Patients were excluded if Ն1 of the following conditions were present: major trauma, surgery requiring anesthesia, or hospitalization within 12 weeks; acute infection requiring antibiotic therapy; change in usual diet within 1 month; pregnancy, breast-feeding, or postpartum within 6 months; myocardial infarction within 12 weeks; any unstable medical condition; life expectancy Ͻ6 months; or treatment with an investigational lipid-altering drug or device within 30 days of the study visit. All patients gave written informed consent, and the study was approved by an institutional review board when required.
The goal for enrollment was 3000 patients in the United States; 1000 patients each in Canada, Spain, the Netherlands, France, Taiwan, and Korea; 400 patients in Brazil; and 600 patients in Mexico. Cluster sampling was used, with a cluster defined as each practicing physicianinvestigator. Each investigator was expected to enroll Ϸ20 patients.
Study Protocol
Data on history of smoking, alcohol use, past coronary disease or other atherosclerotic events, hypertension, diabetes mellitus, family history of coronary or atherosclerotic disease, hypothyroidism, nephrotic syndrome, liver disease, and any other significant medical condition were obtained from each patient at the study visit. Current cholesterol medications, if any, and duration of therapy and any nonpharmacological interventions for dyslipidemia (diet, exercise) were recorded. Height, weight, waist circumference, and blood pressure were measured. A venous blood sample was drawn in patients after fasting for at least 8 hours. All samples were analyzed in a central laboratory (MDS Pharma Services Central Laboratory, Mississauga, Ontario, Canada) for total cholesterol, HDL-C, triglycerides, blood glucose, and high-sensitivity C-reactive protein with a Roche Modular Analyzer; LDL-C was calculated by the Friedewald formula. Framingham 10-year risk of developing a coronary event was calculated for each patient.
Statistical Analyses
Sample Size Determination
The primary end point of success rate would have a 2% margin of error at a 0.05 level of significance, assuming a success rate of 50%, if the sample size were 2401. The enrollment goal was set at 3000 patients in the United States, 3000 patients in Europe (1000 each in Spain, the Netherlands, and France), 2000 patients in Asia (1000 each in Taiwan and Korea), and 1000 in South America (400 in Brazil and 600 in Mexico). The margin of error for the primary end point was thus Ͻ2% in the United States and Ͼ2% in the geographic groups with smaller numbers of participants.
Study End Points
The primary end point was success rate, defined as the proportion of patients achieving LDL-C treatment goals. NCEP ATP III guidelines were used for the United States, Latin America, and Asia; Joint European guidelines were used for patients in European countries; and Canadian guidelines were used for patients in Canada. For HDL-C, the primary end point was defined as the proportion of patients within categories of HDL-C (Ͻ40, 40 to 60, and Ͼ60 mg/dL). Secondary efficacy parameters were levels of LDL-C, HDL-C, total cholesterol, triglycerides, and high-sensitivity C-reactive protein.
LDL-C success rates were compared among risk groups with the 2 test. Multivariate predictors of LDL-C success rates and HDL-C levels were determined from logistic regression models. Normally distributed data are expressed as meanϮSD; nonnormally distributed data such as high-sensitivity C-reactive protein levels are expressed as median values with interquartile ranges.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
A total of 10 174 patients were enrolled, but 219 (2.2%) were excluded because of missing LDL-C values, leaving a study population of 9955. The clinical characteristics of the patients enrolled in each country are listed in Table 1 . Overall, the average age of the patients was 62Ϯ12 years, and 54% were male. Coronary disease had been diagnosed in 30%, diabetes in 31%, hypertension in 64%, a family history of premature coronary disease in 29%, and current smoking in 14%. Current treatment consisted of a statin in 75% of patients, a fibrate in 7%, ezetimibe in 5%, simvastatin/ezetimibe in 5%, and nonpharmacological therapy only in 16%. Niacin, omega-3/fish oil, and bile acid sequestrants each were used by Ͻ2% of the study population. The most commonly used statins were atorvastatin in 33% of patients, simvastatin in 17%, rosuvastatin in 12%, and pravastatin in 7%. The median duration of statin therapy was 2.0 years (interquartile range, 0.8 to 3.6 years).
Patients were classified into low-, moderate-, and high-risk groups, with low-risk patients being those with Յ1 risk factor, moderate-risk patients being those with Ն2 risk factors, and high-risk patients being those with coronary or other atherosclerotic vascular disease or diabetes mellitus. The characteristics of the patients in each group are listed in Table 2 .
LDL-C Success Rate
Overall, 7239 of the 9955 patients attained their LDL-C goal, for a success rate of 73%. The rate was 86% (1782 of 2066) in low-risk patients, 74% (1459 of 1959) in moderate-risk patients, and 67% (3998 of 5930) in high-risk patients (PϽ0.001). Among low-risk patients, mean LDL-C was 108Ϯ27 mg/dL (2.8Ϯ0.7 mmol/L) among those who successfully reached goal and 185Ϯ24 mg/dL (4.8Ϯ0.6 mmol/L) among those who did not. In moderate-risk patients, mean LDL-C was 92Ϯ22 mg/dL (2.4Ϯ0.6 mmol/L) in those who reached goal and 158Ϯ23 mg/dL (4.1Ϯ0.6 mmol/L) in those who did not. In the high-risk group, mean LDL-C was 73Ϯ17 mg/dL (1.9Ϯ0.4 mmol/L) in those who reached goal and 127Ϯ28 mg/dL (3.3Ϯ0.7 mmol/L) in those who did not.
The success rate varied considerably by country, from a low of 47% to a high of 84% ( Figure 1A ). As shown in Figure 1B , success rates were higher in moderate/high-risk patients in the 3 European countries but higher in low-risk patients in the other countries. The success rate was higher in men than in women, 74% compared with 72% (PϽ0.0001). Multivariate predictors of successful LDL-C goal achievement were lipid-lowering therapy (PϽ0.0001), lower-risk group (PϽ0.0001), geographic region (PϽ0.0001), male gender (PϽ0.0001), older age (PϽ0.0001), race (AsianϾwhiteϾblack; PϽ0.0001), absence of dietary counseling (PϽ0.0001), diabetes (Pϭ0.0028), and hypertension (Pϭ0.0105).
The success rate for non-HDL-C goals ranged from a low of 60% to a high of 84%, as illustrated in Figure 1C . Non-HDL-C goals are not part of the European or Canadian guidelines.
In patients with CHD and Ն2 risk factors, an optional LDL-C treatment target of Ͻ70 mg/dL (1.8 mmol/L) has been recommended by the NCEP since 2004. 6 Among the 2334 L-TAP 2 patients in this very-high-risk category, 704 (30%) attained this goal. In the United States, 274 (35%) of 511 very-high-risk patients achieved this goal. The success rate in other countries (where this goal was not part of national guidelines) ranged from 16% to 37%.
HDL-C Levels
HDL-C levels for low-, moderate-, and high-risk patients are listed in Table 2 . Overall, 19% of patients had an HDL-C level Ͻ40 mg/dL (1.0 mmol/L), and 26% had a level Ͼ60 mg/dL (1.6 mmol/L). Low-risk patients had substantially higher HDL-C levels than moderate-or high-risk patients did. (At least part of the reason for this was that a high HDL-C level counted as a negative risk factor.) Among low-risk patients, only 7% had an HDL-C Ͻ40 mg/dL (1.0 mmol/L) compared with 55% who had an HDL-C Ͼ60 mg/dL (1.6 mmol/L). In moderate-and high-risk patients, 20% and 23%, respectively, had an HDL-C level Ͻ40 mg/dL (1.0 mmol/L).
If low HDL-C is defined as Ͻ40 mg/dL (1.0 mmol/L) in men and Ͻ50 mg/dL (1.3 mmol/L) in women, 27% of men (1453 of 5413) and 32% of women (1453 of 4512) had low HDL-C levels. With this definition, in the high-risk group, 30% of men (1067 of 3576) and 38% of women (900 of 2353) had low HDL-C levels.
Predictors of low HDL-C levels in men were higher body mass index, lower LDL-C, geographic region, smoking, nonstatin lipid therapy, younger age (all PϽ0.0001), and diabetes (Pϭ0.0001). Predictors of low HDL-C levels in females were larger waist circumference, geographic region, diabetes, younger age, lower LDL-C (all PϽ0.0001), smoking (Pϭ0.0006), hypertension (Pϭ0.007), and nonstatin lipid therapy (Pϭ0.019).
The distribution of low, intermediate, and high HDL-C levels by country is shown in Figure 2 . The proportion of patients with low HDL-C was Ͼ20% in Canada and the United States and Ͻ12% in France, Spain, and Brazil. France, (14) 362 (12) 160 (16) 137 (14) 210 (22) 155 (16) 18 (5) 60 (10) 122 (12) 132 (14) Low HDL-C 790 (8) 327 (11) 120 (12) 24 (3) 62 (7) 36 (4) 12 (3) 43 (7) 84 (9) 79 (8) No (8) 314 (10) 61 (6) 170 (18) 69 (7) 70 (7) 9 (2) 39 (7) 16 (2) 85 (9) Dietary counseling, (%) 6569 (68) 2178 (74) 709 (71) 814 (89) 545 (58) 950 (98) 344 (90) 534 (89) 8 (1) 481 (50) Risk category, (%) Low 2066 (21) 595 (20) 157 (15) 349 (36) 133 (14) 374 (38) 82 (21) 163 (27) 111 (11) 102 (11) Moderate 1959 (20) 681 (22) 207 (20) 162 (17) 177 (18) 215 (21) 100 (26) 110 (18) 205 (21) 102 (11) High/CHD 5930 (59) 1773 (58) 657 (65) 453 (47) 655 (68) 416 (41) 209 (53) 338 (55) 667 (68) 762 (78) Lipid measurements, mg/dL LDL-C  100Ϯ37  98Ϯ36  94Ϯ34  113Ϯ37  97Ϯ33  119Ϯ38  113Ϯ46  98Ϯ40  84Ϯ27  98Ϯ31   HDL-C  53Ϯ15  51Ϯ15  49Ϯ13  60Ϯ16  52Ϯ15  57Ϯ15  54Ϯ14  51Ϯ13  50Ϯ12  52Ϯ14   Non-HDL-C  130Ϯ41  129Ϯ42  124Ϯ39  140Ϯ41  126Ϯ36  146Ϯ40  142Ϯ49  136Ϯ47  111Ϯ29  127Ϯ35   Triglycerides  152Ϯ86  158Ϯ101  154Ϯ96  138Ϯ71  149Ϯ69  138Ϯ67  145Ϯ67  189Ϯ106  139Ϯ61  148Ϯ71 Triglycerides/HDL-C 3.3Ϯ2. 115Ϯ39  115Ϯ40  116Ϯ32  107Ϯ31  122Ϯ42  116Ϯ38  110Ϯ41  114Ϯ50  106Ϯ27  124Ϯ45 BMI indicates body mass index; hs-CRP, high-sensitivity C-reactive protein, which is reported as median (interquartile range). Values are meanϮSD when appropriate.
Spain, and Brazil had the highest proportion of patients with an HDL-C level Ͼ60 mg/dL (1.6 mmol/L).
Discussion
The results of this survey indicate that the proportion of patients attaining LDL-C treatment goals is much higher than it was a decade ago. Overall, 73% of patients reached their LDL-C goal; in high-risk patients, the rate was 67%. The comparative rates in the original L-TAP survey done 10 years earlier (in 1996 to 1997) were 38% and 18%. Despite this improvement, one third of high-risk patients remain inadequately treated. Using the more recently recommended optional goal of Ͻ70 mg/dL (1.8 mmol/L) for very-high-risk patients (CHD plus Ն2 major risk factors), we find that the success rate was only 30%. More aggressive treatment of patients not meeting goals and improving success rates in underperforming countries have the potential to further reduce cardiovascular risk.
Other Studies
Previous studies have reported a wide range of success rates in attaining LDL-C goals. The differences appear to be related mainly to differences in patient populations and among treating physicians. In the NCEP Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey conducted in 2003 among physicians who were high prescribers of cholesterol drugs, 67% of 4885 patients achieved their LDL-C goal according to NCEP ATP III. 10 Among those at very high risk, only 18% attained the optional goal of Ͻ70 mg/dL (1.8 mmol/L). In a Canadian study of 8056 patients with CHD, diabetes, or both recruited between 2001 and 2004, 51% of patients reached their LDL-C goal. 12 On the other hand, in a study of 110 primary care practices in Germany between 1998 and 2005, only 29% of 79 689 patients had attained their LDL-C goal at the last follow-up visit. 13 Data from 7399 individuals in the National Health and Nutrition Examination Survey (NHANES) in the United States between 1999 and 2002 were used to estimate the proportion of the adult population nationwide between 20 and 79 years of age who achieved NCEP ATP III goals. 11 Overall, 66% of patients met their LDL-C goal, but among very-high-risk patients, only 4.6% had an LDL-C Ͻ70 mg/dL (1.8 mmol/L).
A limitation of our study, and other similar studies, is that we do not know to what extent the physicians and patients are representative. It may be that physicians involved in our study are more successful at achieving treatment goals than those who did not participate.
An achievement, 38% in L-TAP and 73% in L-TAP 2, represents a definite and substantial improvement. More impressively, among patients with CHD in L-TAP, the success rate was only 18% compared with 67% in L-TAP 2 among high-risk patients (those with CHD, other atherosclerotic vascular disease, or diabetes). Longer exposure to more stringent guidelines and more potent statins likely accounts for this marked improvement.
Only 30% of L-TAP 2 patients at very high risk attained the optional LDL-C target of Ͻ70 mg/dL (1.8 mmol/L). Although this is superior to the 18% rate in NEPTUNE II 10 and the 4.6% rate in NHANES, 11 substantial room for improvement remains. Although very-high-risk patients make up only a small minority of the population, their very high event rate makes them a worthy focus of the most aggressive treatment. Joint European Societies guidelines for France, the Netherlands, and Spain. B, Proportion of patients attaining LDL-C target levels in each country according to risk group. Group 1 refers to low-risk patients; group 2, moderate-risk patients (except in the European countries where the guidelines group moderate-and highrisk patients together); and group 3, highrisk patients for the non-European countries. Success rates are higher in moderate/high-risk patients in the European countries but higher in low-risk patients in the other countries. C, Proportion of patients attaining non-HDL-C target levels in each country. Non-HDL-C goals are not a part of either the European or Canadian guidelines.
